GlaxoSmithKline
Haleon’s debut suggests it may not be the jewel in GSK’s medicine cabinet | Nils Pratley
Consumer goods spin-off makes few waves in biggest European listing for more than a decade
Nils Pratley
18, Jul, 2022 @5:40 PM
GSK spin-off Haleon begins trading in biggest European listing in a decade
Consumer health company ends first day on London Stock Exchange with £28.5bn market valuation
Mark Sweney and Julia Kollewe
18, Jul, 2022 @8:31 AM
London stock market listing of up to £45bn looms as GSK investors vote for demerger
UK pharmaceutical firm to spin off Haleon – which will include brands such as Sensodyne and Panadol – in largest listing since 2011
Jasper Jolly
06, Jul, 2022 @5:16 PM
Hundreds of organisations breached patient data rules, reveals BMJ
Drug firms, private healthcare providers and universities among those that may be failing to protect confidentiality, says report
Andrew Gregory Health editor
11, May, 2022 @10:30 PM
Boots, Superdrug and other chemists report hay fever pill shortages
GlaxoSmithKline blames temporary manufacturing issues for lack of Piriton tablets
Julia Kollewe
10, May, 2022 @10:53 AM
GSK to buy US cancer drug developer amid pressure from activist investor
GlaxoSmithKline’s £1.5bn Sierra Oncology deal comes after pressure from Elliott to boost its pipeline
Jasper Jolly and agencies
13, Apr, 2022 @12:03 PM
GlaxoSmithKline says it will not start any new clinical trials in Russia
Pharma firm joins AstraZeneca and Pfizer in saying it will not enrol new patients into studies
Julia Kollewe
17, Mar, 2022 @12:28 PM
BP and Shell lead rush to exit Russia. There can be no going back
Oil is always a political business, and there’s no point pretending otherwise
Nils Pratley
28, Feb, 2022 @7:40 PM
GSK boss upbeat over spin-off of consumer healthcare unit
Expected to be the biggest London listing in a decade, the Haleon demerger is scheduled for July
Jasper Jolly
28, Feb, 2022 @2:53 PM
GSK unveils its new consumer brands spin-off name: Haleon
Products such as Voltaren, Sensodyne and Panadol to regroup under new stock market listing in summer
Julia Kollewe
22, Feb, 2022 @4:13 PM
Screeching U-turn as Unilever’s shareholders balk at £50bn GSK deal
Riot in ranks sends ‘strong message’ against tilt at GlaxoSmithKline’s consumer division
Nils Pratley
10, Feb, 2022 @7:47 PM
Noisy activists aside, GSK investors backed Walmsley and her strategy
The ‘step-change’ in growth for the core pharma division has barely started, but the CEO is secure for now
Nils Pratley
09, Feb, 2022 @7:04 PM
1 / 75 pages